openPR Logo
Press release

C-MET Non-Small Cell Lung Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

03-17-2025 01:23 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

C-MET Non-Small Cell Lung Cancer Pipeline

C-MET Non-Small Cell Lung Cancer Pipeline

DelveInsight's, "C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Pipeline Insight" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the c-MET-NSCLC Treatment Landscape. Click here to read more @ c-MET-NSCLC Pipeline Outlook- https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the c-MET-NSCLC Pipeline Report
• In January 2025:- AbbVie:- A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
• DelveInsight's c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for c-MET-NSCLC treatment.
• The leading c-MET-NSCLC Companies such as AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
• Promising C-MET NSCLC Therapies such as Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others.

Stay informed about the cutting-edge advancements in c-MET NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ c-MET NSCLC Clinical Trials Assessment- https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

c-MET NSCLC Emerging Drugs Profile

• JNJ-61186372: Janssen Research & Development, LLC
JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations and amplifications. The production and development of the antibody followed Janssen's licensing agreement with Genmab for use of its DuoBody technology platform. According to the company, JNJ-6372 is a novel bispecific antibody that has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.

• PLB1001 - Beijing Pearl Biotechnology Limited Liability Company
PLB1001 is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, PLB1001 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

Learn more about c-MET NSCLC Drugs opportunities in our groundbreaking c-MET NSCLC Research and development projects @ c-MET NSCLC Unmet Needs- https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

c-MET NSCLC Companies
AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.

C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intramuscular
• Intratumoral
• Intravenous
• Molecule Type

c-MET NSCLC Products have been categorized under various Molecule types such as
• Gene therapies
• Bispecific antibodies
• Immunotherapies
• Monoclonal antibodies
• Small molecules
• Product Type

Discover the latest advancements in c-MET NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ c-MET NSCLC Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the c-MET NSCLC Pipeline Report
• Coverage- Global
• c-MET NSCLC Companies- AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
• C-MET NSCLC Therapies- Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others.
• c-MET NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• c-MET NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of c-MET NSCLC Pipeline on our website @ c-MET NSCLC Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Collaboration Deals
9. Mid Stage Products (Phase II)
10. Telisotuzumab: AbbVie
11. PLB1001: Beijing Pearl Biotechnology Limited Liability Company
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. JNJ-61186372: Janssen Research & Development, LLC
15. Drug profiles in the detailed report.....
16. Pre-clinical and Discovery Stage Products
17. Drug profiles in the detailed report.....
18. Inactive Products
19. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
20. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Products
21. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Unmet Needs
22. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Market Drivers and Barriers
23. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Future Perspectives and Conclusion
24. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Analyst Views
25. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
26. Appendix

List of Top Selling Market Research Reports in 2025

Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release C-MET Non-Small Cell Lung Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here

News-ID: 3919208 • Views:

More Releases from DelveInsight Business Research LLP

Mobile Clinics Market Forecast Report 2032: Size, Share, and Strategic Insights by DelveInsight
Mobile Clinics Market Forecast Report 2032: Size, Share, and Strategic Insights …
DelveInsight's Mobile Clinics Market Insights Report 2032 provides the current and forecast market analysis, individual leading Mobile Clinics Companies market shares, challenges, Mobile Clinics Market Drivers, barriers, trends, and key market Mobile Clinics companies in the market. To read more about the latest highlights related to the Mobile Clinics Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/Mobile-Clinics-Market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Mobile Clinics Market
Vein Illumination Devices Market Outlook Report 2032: Current Scenario, Growth Opportunities, and Future Trends by DelveInsight
Vein Illumination Devices Market Outlook Report 2032: Current Scenario, Growth O …
DelveInsight's Vein Illumination Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Vein Illumination Devices Companies market shares, challenges, Vein Illumination Devices Market Drivers, barriers, trends, and key market Vein Illumination Devices companies in the market. To read more about the latest highlights related to the Vein Illumination Devices Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key
Bioanalytical Testing Services Market Forecast Report 2032: Size, Share, and Strategic Insights by DelveInsight
Bioanalytical Testing Services Market Forecast Report 2032: Size, Share, and Str …
DelveInsight's Bioanalytical Testing Services Market Insights Report 2032 provides the current and forecast market analysis, individual leading Bioanalytical Testing Services Companies market shares, challenges, Bioanalytical Testing Services Market Drivers, barriers, trends, and key market Bioanalytical Testing Services companies in the market. To read more about the latest highlights related to the Bioanalytical Testing Services Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/bioanalytical-testing-services-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key
Thyroid Gland Disorder Treatment Market Forecast Report 2032 by DelveInsight: Size, Share, and Strategic Insights
Thyroid Gland Disorder Treatment Market Forecast Report 2032 by DelveInsight: Si …
DelveInsight's Thyroid Gland Disorder Treatment Market Insights Report 2032 provides the current and forecast market analysis, individual leading Thyroid Gland Disorder Treatment Companies market shares, challenges, Thyroid Gland Disorder Treatment Market Drivers, barriers, trends, and key market Thyroid Gland Disorder Treatment companies in the market. To read more about the latest highlights related to the Thyroid Gland Disorder Treatment Market, get a snapshot of the key highlights entailed in the Market

All 5 Releases


More Releases for MET

I Met Jesus Presented By RISING STAR
RISING STAR, the innovative fashion house based in New York City, presents the timeless art collection, entitled I Met Jesus. I Met Jesus, includes several limited subcollections, I Met Jesus 5 Times This Year and He Named My Brand, I Met Jesus 5 Times Again...3 Times in January and I Met Jesus 10 Times. In total, the collection contains just over 100 photographs, which have received individual listings that range
Global Potassium Met Bisulfite Market Research
Global Potassium Met Bisulfite Market advertise is foreseen to develop at a CAGR of 4.56% in the determined year. The interest for potassium metabisulfite is significantly determined by development in the interest for wine and brew fabricating enterprises. Likewise, the development of the nourishment additives industry is moreover driving the development of Global Potassium Met Bisulfite Market in nations with strict direction on non-sustenance synthetic compounds utilized in nourishment and
Het Beveiligen Van uw Bedrijf met Arbeidsongeschiktheidsverzekering Vergelijken
Het vergelijken van arbeidsongeschiktheidsverzekeringen is een frequent hulpmiddel om te bepalen wat je het meeste baten mogelijk met uw geïnvesteerde premies. Niet alleen springen in een applicatie, omdat het voorspelt ruime vergoedingen en niet-belastbare terugbetaling. U kunt op dit moment beseffen dat je in feite meer betalen aan de superieure behouden, dan profiteren van de voordelen waarmee je vooral kocht de arbeidsongeschiktheidsverzekering voor. Wanneer u Arbeidsongeschiktheidsverzekering vergelijken, loopt u het risico
Met Office Launch Eco T-Shirt Range
The Met Office has teamed up with Rapanui, an eco-fashion company, to create a range of weather related T-shirts just in time for summer. The Met Office eco clothing collection is made from organic cotton in an ethical, wind powered factory and features a range of weather related designs inspired by the imagery, science and history of the Met Office. Mart Drake-Knight co-founder of Rapanui said: “The Met Office is the international
When Cleankill met Sarah Beeny
Staff from Surrey-based Cleankill Pest Control are celebrating after appearing on national television. The pest experts were thrilled when they were contacted recently by well-known TV presenter Sarah Beeny to solve a clothes moth problem in a London woman’s house. Sarah asked Cleankill to help architect Kate Grose whose clothes were being eaten away in her two-bed maisonette. Cleankill Managing Director Paul Bates was filmed showing where to look
Met Office launches interactive 4C climate change map
The Met Office unveils Interactive map to illustrate a 4C temperatures rise by 2060, reports Envido. The Met Office launched yesterday a new interactive map designed to illustrate the impact of climate change with an average global temperature rise of 4C. The interactive map follows the release last month of new research saying that the catastrophic increase in temperature could occur as early as 2060 if global GHG emissions do not peak